Fairmount Funds Management LLC - 24 Nov 2023 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role: Director, 10%+ Owner
Signature: /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Issuer symbol: SYRE
Transactions as of: 24 Nov 2023
Net transactions value: $0
Form type: 4
Filing time: 28 Nov 2023, 16:05:26 UTC
Previous filing: 01 Nov 2023
Next filing: 11 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGLE	Common Stock	Conversion of derivative security	$0	+3,435,480	$0.000000	3,435,480	24 Nov 2023	By Fairmount Healthcare Co-Invest L.P.	F1, F2
holding	AGLE	Common Stock					11,043	24 Nov 2023	By Fairmount Healthcare Fund L.P.	F2
holding	AGLE	Common Stock					367,378	24 Nov 2023	By Fairmount Healthcare Fund II L.P.	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Ownership	Footnotes
transaction	AGLE	Series A Preferred Stock	Conversion of derivative security	$0	-85,887	-100%	$0.000000^*	0	24 Nov 2023	Common Stock	3,435,480	By Fairmount Healthcare Co-Invest L.P.	F1, F2
holding	AGLE	Series A Preferred Stock						12,675	24 Nov 2023	Common Stock	507,000	By Fairmount Healthcare Fund L.P.	F1, F2
holding	AGLE	Series A Preferred Stock						424,362	24 Nov 2023	Common Stock	16,974,480	By Fairmount Healthcare Fund II L.P.	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations.
F2	Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Content

Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations.

Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Remarks:

The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of Issuer and are also each a Managing Member of Fairmount Funds Management LLC.